Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has secured a group purchasing organization (GPO) agreement that provides coverage for its FDA-approved non-opioid fibromyalgia treatment, TONMYA (cyclobenzaprine HCl sublingual tablets), to approximately 35 million U.S. commercial lives, representing about 20% of the commercial market. The agreement, effective May 1, 2026, includes standard utilization management criteria and marks a key milestone in the company's strategy to broaden patient access to this recently approved therapy.
The importance of this agreement lies in its potential to significantly increase the number of patients who can access TONMYA, which is the first new treatment for fibromyalgia in over 15 years. Fibromyalgia affects an estimated 6-12 million people in the United States, and many patients have limited treatment options, often relying on off-label medications. By securing coverage through a leading GPO, Tonix aims to facilitate physician prescribing and patient access, potentially driving adoption of this non-opioid alternative. The company is also pursuing additional coverage across commercial and government channels, with existing Medicaid coverage in 38 states representing approximately 55 million lives.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA, the company's flagship medicine, is administered as a sublingual tablet and offers a novel mechanism of action for fibromyalgia management. The company's CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra. Beyond TONMYA, Tonix is advancing a pipeline that includes TNX-2900 for Prader-Willi syndrome, monoclonal antibody TNX-4800 for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for prevention of kidney transplant rejection. These product development candidates are investigational and have not been approved for any indication.
The GPO agreement is a critical step in Tonix's commercialization efforts for TONMYA, as it provides a pathway for broad insurance coverage that can influence formulary placement and patient out-of-pocket costs. With the GPO covering a substantial portion of the commercial market, Tonix is positioned to compete more effectively in the fibromyalgia treatment landscape. The company's strategy includes leveraging this agreement to secure additional contracts and expand its footprint in both commercial and government payer segments. Tonix continues to engage with payers and healthcare providers to ensure that patients have access to this non-opioid option, which may offer a safer alternative for chronic pain management.
